Vol 2, No 1 (March 2013): Chinese Clinical Oncology

Editorials

Can EGFR mutation status evolve with chemotherapy?
Eric S. Kim, David J. Stewart, Alok A. Khorana
Chinese Clinical Oncology
 2013;
2
(1)
:1
EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy
Jair Bar, Damien Urban, Roni Borshtein, Hovav Nechushtan, Amir Onn
Chinese Clinical Oncology
 2013;
2
(1)
:2
Drifting EGFR mutation
Rintaro Noro, Tesshi Yamada
Chinese Clinical Oncology
 2013;
2
(1)
:3

Original Article

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments
Laura E. Johnson, Jordan T. Becker, Jason A. Dubovsky, Brian M. Olson, Douglas G. McNeel
Chinese Clinical Oncology
 2013;
2
(1)
:4

Perspective

Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant
Valerie Nelson, Alfred Rademaker, Virginia Kaklamani
Chinese Clinical Oncology
 2013;
2
(1)
:10